GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (STU:ZR8) » Definitions » Other Income (Expense)

Oncodesign Precision Medicine (STU:ZR8) Other Income (Expense) : € Mil (TTM As of Jun. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Other Income (Expense)?

Oncodesign Precision Medicine's other income expense for the Oncodesign Precision Medicine's pretax income for the six months ended in Jun. 2022 was €0.00 Mil.


Oncodesign Precision Medicine Other Income (Expense) Historical Data

The historical data trend for Oncodesign Precision Medicine's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Other Income (Expense) Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
Other Income (Expense)
- -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
Other Income (Expense) - - -

Oncodesign Precision Medicine Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.


Oncodesign Precision Medicine  (STU:ZR8) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Oncodesign Precision Medicine (STU:ZR8) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (STU:ZR8) Headlines

No Headlines